Assessing the cost-effectiveness of pharmacogenomics
Journal Title: The AAPS Journal - Year 2000, Vol 2, Issue 3
Abstract
The use of pharmacogenomics to individualize drug therapy offers the potential to improve drug effectiveness, reduce adverse side effects, and provide cost-effective pharmaceutical care. However, the combinations of disease, drug, and genetic test characteristics that will provide clinically useful and economically feasible therapeutic interventions have not been clearly elucidated. The purpose of this paper was to develop a framework for evaluating the potential cost-effectiveness of pharmacogenomic strategies that will help scientists better understand the strategic implications of their research assist in the design of clinical trials, and provide a guide for health care providers making reimbursement decisions. We reviewed concepts of cost-effectiveness analysis and pharmacogenomics and identified 5 primary characteristics that will enhance the cost-effectiveness of pharmacogenomics: 1) there are severe clinical or economic consequence that are avoided through the use of pharmacogenomics, 2) monitoring drug response using current methods is difficult, 3) a well-established association between genotype and clinical phenotype exists, 4) there is a rapid and relatively inexpensive genetic test, and 5) the variant gene is relatively common. We use this framework to evaluate several examples of pharmacogenomics. We found that pharmacogenomics offers great potential to improve patients' health in a cost-effective manner. However, pharmacogenomics will not be applied to all currently marketed drugs, and careful evaluations are needed on a case-by-case basis before investing resources in research and development of pharmacogenomic-based therapeutics and making reimbursement decisions.
Authors and Affiliations
David L. Veenstra, Mitchell K. Higashi, Kathryn A. Phillips
Keywords
Related Articles
- EP ID EP682107
- DOI 10.1208/ps020329
- Views 73
- Downloads 0
Multidimensional Atomic Force Microscopy: A Versatile Novel Technology for Nanopharmacology Research
The online version of this article (doi:10.1208/s12248-010-9232-y) contains supplementary material, which is available to authorized users.
A random sampling approach for robust estimation of tissue-to-plasma ratio from extremely sparse data
This study was performed to develop a new nonparametric approach for the estimation of robust tissue-to-plasma ratio from extremely sparsely sampled paired data (ie, one sample each from plasma and tissue per subject). T...
Study of crystallization of endogenous surfactant in Eudragit NE30D-Free films and its influence on drug-release properties of controlled-release diphenhydramine HCI pellets coated with Eudragit NE30D
This study investigates the crystallization of the endogenous surfactant nonoxynol 100 in Eudragit NE30D-free films during storage and the influences of nonoxynol 100 on the dissolution of diphenhydramine hydrochloric ac...
Application of a Physiologically Based Pharmacokinetic Model Informed by a Top-Down Approach for the Prediction of Pharmacokinetics in Chronic Kidney Disease Patients
The online version of this article (doi:10.1208/s12248-014-9626-3) contains supplementary material, which is available to authorized users.
In vitro–In Vivo Correlations: Tricks and Traps
In vitro–in vivo correlation (IVIVC) is a biopharmaceutical tool recommended to be used in development of formulation. When validated, it can speed up development of formulation, be used to fix dissolution limits...